JVJörg Janne Vehreschild

Jörg Janne Vehreschild

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jörg Janne Vehreschild has a total of 96 co-authors. Here are the top co-authors by number of shared publications:

  • Melanie Stecher

    University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I for Internal Medicine, Cologne, Germany; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Germany

    2 shared publications
  • Oliver A. Cornely

    University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I for Internal Medicine, Cologne, Germany; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Chair Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany

    2 shared publications
  • Alexander Bartschke

    Berlin Institute of Health at Charité‒Universitätsmedizin Berlin, Berlin, Germany

    1 shared publication
  • Andreas Engert

    University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I for Internal Medicine, Cologne, Germany

    1 shared publication
  • Anna Horn

    Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-Universität Würzburg, Würzburg, Germany

    1 shared publication
  • Anna-Lena Hofmann

    Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany

    1 shared publication

Latest Publications

  • Open Access

    The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics

    by Maximilian Schons, Lisa Pilgram, Jens-Peter Reese, Melanie Stecher, Gabriele Anton, Katharina S. Appel, Thomas Bahmer, Alexander Bartschke, Carla Bellinghausen, Inga Bernemann, et al.

    The German government initiated the Network University Medicine (NUM) in early 2020 to improve national research activities on the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic. To this end, 36 German Academic Medical Centers started to collaborate on 13 projects, with the largest being the National Pandemic Cohort Network (NAPKON). The NAPKON’s goal is creating the most comprehensive Coronavirus Disease 2019 (COVID-19) cohort in Germany. Within NAPKON, adult and pediatric patients are observed in three complementary cohort platforms (Cross-Sectoral, High-Resolution and Population-Based) from the initial infection until up to three years of follow-up. Study procedures comprise comprehensive clinical and imaging diagnostics, quality-of-life assessment, patient-reported outcomes and biosampling. The three cohort platforms build on four infrastructure core units (Interaction, Biosampling, Epidemiology, and Integration) and collaborations with NUM projects. Key components of the data capture, regulatory, and data privacy are based on the German Centre for Cardiovascular Research. By April 01, 2022, 34 university and 40 non-university hospitals have enrolled 5298 patients with local data quality reviews performed on 4727 (89%). 47% were female, the median age was 52 (IQR 36–62-) and 50 pediatric cases were included. 44% of patients were hospitalized, 15% admitted to an intensive care unit, and 12% of patients deceased while enrolled. 8845 visits with biosampling in 4349 patients were conducted by April 03, 2022. In this overview article, we summarize NAPKON’s design, relevant milestones including first study population characteristics, and outline the potential of NAPKON for German and international research activities. Trial registration https://clinicaltrials.gov/ct2/show/NCT04768998 . https://clinicaltrials.gov/ct2/show/NCT04747366 . https://clinicaltrials.gov/ct2/show/NCT04679584


  • Association between the dietary regimen and infection-related complications in neutropenic high-risk patients with cancer

    by Carolin E.M. Jakob, Annika Y. Classen, Melanie Stecher, Andreas Engert, Meike Freund, Axel Hamprecht, Nathalie Jazmati, Hilmar Wisplinghoff, Michael Hallek, Oliver A. Cornely, et al.


  • Association Between Prescribed Opioids and Infections in Patients With Neutropenia and Cancer

    by Carolin E. M. Jakob, Melanie Stecher, Annika Y. Claßen, Axel Hamprecht, Oliver A. Cornely, Jörg J. Vehreschild

    In a recent article, Edelman and colleagues1 identified an association between prescribed opioids and risk for community-acquired pneumonia among patients with and without HIV infection. This is of concern for immunocompromised patients receiving opioids for cancer pain. We used the prospective Cologne Cohort of Neutropenic Patients (NCT01821456) to confirm this observation in patients with chemotherapy-induced neutropenia. Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.


  • Open Access

    Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients

    by Jörg Janne Vehreschild, Philipp Koehler, Frédéric Lamoth, Juergen Prattes, Christina Rieger, Bart J A Rijnders, Daniel Teschner

    Diagnosis, treatment, and management of invasive mould infections (IMI) are challenged by several risk factors, including local epidemiological characteristics, the emergence of fungal resistance and the innate resistance of emerging pathogens, the use of new immunosuppressants, as well as off-target effects of new oncological drugs. The presence of specific host genetic variants and the patient's immune system status may also influence the establishment of an IMI and the outcome of its therapy. Immunological components can thus be expected to play a pivotal role not only in the risk assessment and diagnosis, but also in the treatment of IMI. Cytokines could improve the reliability of an invasive aspergillosis diagnosis by serving as biomarkers as do serological and molecular assays, since they can be easily measured, and the turnaround time is short. The use of immunological markers in the assessment of treatment response could be helpful to reduce overtreatment in high risk patients and allow prompt escalation of antifungal treatment. Mould-active prophylaxis could be better targeted to individual host needs, leading to a targeted prophylaxis in patients with known immunological profiles associated with high susceptibility for IMI, in particular invasive aspergillosis. The alteration of cellular antifungal immune response through oncological drugs and immunosuppressants heavily influences the outcome and may be even more important than the choice of the antifungal treatment. There is a need for the development of new antifungal strategies, including individualized approaches for prevention and treatment of IMI that consider genetic traits of the patients. Lay Abstract Anticancer and immunosuppressive drugs may alter the ability of the immune system to fight invasive mould infections and may be more important than the choice of the antifungal treatment. Individualized approaches for prevention and treatment of invasive mold infections are needed.


  • Infektiologie – Pionier der Digitalen Medizin

    by Jörg Janne Vehreschild, Annika Yanina Claßen, Carolin Jakob

    Was ist neu?: Von der personalisierten zur digitalen Medizin Über Impfungen und gezielte Erregerdiagnostik und -therapie ist die Infektionsmedizin Vorreiterin der personalisierten Medizin. Datenprozesse im Rahmen neuer Infektionsepidemien sind Musterbeispiele der Möglichkeiten der digitalen Medizin. Klinische Entscheidungshilfen Die oft gut definierten Krankheitsbilder der Infektiologie und das hohe Niveau der verfügbaren Leitlinien sind ideale Voraussetzungen für computerunterstützte Behandlungsentscheidungen. Datengetriebene Infektionsforschung Durch die Verbindung von Daten aus elektronischen Patientenakten mit den umfassenden Datensätzen neuer Technologien aus der sogenannten „Omics“-Forschung können neue Zusammenhänge erkannt und Prognosen verbessert werden. Elektronische Gesundheitsakte Die elektronische Gesundheitsakte eröffnet großes Potenzial im Sinne einer zielgerichteten Behandlung, insbesondere bei infektiologischen Notfällen. Telemedizin In Deutschland fehlen Infektiologen, ein Strukturwandel kann nur schrittweise vollzogen werden. Telemedizinische Konsultationen können helfen, infektiologische Expertise in unzureichend versorgte Regionen zu bringen. Mobile Health Die fast vollständige Verbreitung mobiler Digitalgeräte schafft neue Möglichkeiten für die Gestaltung der Arzt-Patient-Kommunikation sowie der heimatnahen Nachsorge. Mobile Versorgung chronischer Infektionen Beim Langzeitmanagement chronischer Erkrankungen sowie bei der Versorgung in Regionen mit schwacher Infrastruktur entstehen Möglichkeiten einer verbesserten medizinischen Behandlung. Balance der Interessen Die Digitale Medizin birgt Risiken durch die Schaffung großer Datensätze mit potenziell stigmatisierenden Patienteninformationen. Softwaresysteme, die Entscheidungen von klinischer Relevanz beeinflussen, bedürfen sorgfältiger Prüfung und Transparenz.